Drug delivery strategies for targeted treatment of inflammatory bowel disease
Author: Lautenschläger C , Schmidt C ,Lange K , , Stallmach A
A well-known limitation to current treatments for inflammatory bowel disease, drugs can be described as producing limited therapeutic efficacy as well as some occurrences of adverse effects. In 2015, a handful of researchers published a peer review article addressing these concerns. The article focuses in on the delivery methods of drugs giving an overview of both current and potential future strategies. The article subsequently concluded that the ‘novel therapeutic approach’ may be more effective in treating IBD patients with the added benefit of reduced adverse effects.
Crohn’s and Colitis Australia would like to thank Europe PMC for permission to use this article.